Spyre Therapeutics Inc. (SYRE) Stock Analysis

Spyre Therapeutics Inc. (SYRE) is a publicly traded company in the HEALTHCARE sector. It trades at $69.16, carries a market capitalization of $6.13B. This page summarizes the public market data, fundamentals, and frequently asked questions for SYRE, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Spyre Therapeutics Inc. currently has a Neutral sentiment score of 0.09.

About Spyre Therapeutics Inc.

Spyre Therapeutics, Inc. is a cutting-edge biotechnology company headquartered in Waltham, Massachusetts, focused on creating transformative antibody therapeutics for inflammatory bowel disease (IBD). By employing advanced antibody engineering techniques, innovative therapeutic combinations, and precision medicine strategies, Spyre aims to effectively target and address significant unmet medical needs in the management of IBD. With a strong pipeline underscored by a commitment to personalized...

GNG Research Analysis

GNG Research scores Spyre Therapeutics Inc. (SYRE) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SYRE.

Frequently Asked Questions

Does SYRE pay dividends?

Spyre Therapeutics Inc. (SYRE) does not currently pay a regular dividend.

What is SYRE's market cap?

Spyre Therapeutics Inc. (SYRE) has a market capitalization of $6.13B with a current stock price of $69.16.